Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25062591 | 0.78 | MEN1 (0.49) | MEN1KMT2AHCRTR2HCRTR1MAPK14 | |
| SCHEMBL1167096 | 0.77 | MEN1 (0.58) | MEN1KMT2AHCRTR2HCRTR1MAPK14 | |
| SCHEMBL9900640 | 0.74 | MEN1 (0.64) | MEN1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL25062733 | 0.72 | MEN1 (0.51) | MEN1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL9586836 | 0.70 | FBP1 (0.51) | MEN1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL9587212 | 0.70 | ALOX5 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL6437289 | 0.69 | FBP1 (0.53) | KMT2A | |
| SCHEMBL15189624 | 0.69 | MEN1 (0.46) | MEN1KMT2AHCRTR2HCRTR1MAPK14 | |
| SCHEMBL30740878 | 0.68 | FBP1 (0.49) | MEN1KMT2AHCRTR2 | |
| SCHEMBL6434567 | 0.68 | FBP1 (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | MEN1 4017/4885KMT2A 2950/4885HCRTR2 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.